上海医药集团股份有限公司（公司简称“上海医药”，上交所股票代号：601607，港交所股票代号：02607）是一家总部位于上海的全国性医药产业集团。公司主营业务覆盖医药研发与制造、分销与零售全产业链，综合排名位居全国医药行业第二，是中国唯一一家在医药产品和分销市场方面均居领先地位的医药上市公司，2012年营业收入680亿元，位列中国企业500强，入选上证180指数、沪深300指数样本股，H股入选恒生指数成分股、摩根斯坦利中国指数（MSCI）。

上海医药研发以创新为长期坚持的方向，致力于为重大疾病和慢性病提供安全有效的治疗药物，2012年研发投入占公司制药业务销售收入4.72%。公司建立了以中央研究院为技术核心的集团总院分院研发体系，拥有1个国家级企业技术中心以及10个省市级企业技术中心，入选十余项“重大新药创制”国家科技重大专项。公司采用开放式研究模式，与中国科学院上海药物所建立了创新药物研发战略联盟，与中国药科大学、沈阳药科大学等建立联合实验室，与日本三菱田边制药株式会社、上海复旦张江生物医药等合作开展创新药物研发；同时，还通过项目引进、合作开发等方法开始进入治疗性抗体领域。

上海医药制造覆盖化学和生物药品、现代中药和保健品、医疗器械等领域，产品聚焦心脑血管类、全身性抗感染类、消化系统和免疫代谢类、神经精神类、抗肿瘤类五大治疗领域，生产片剂、胶囊、粉针（含冻干）、小容量注射液、滴眼剂、气雾剂、凝胶剂等20种以上剂型，过亿产品20个。公司旗下的信谊、雷氏、龙虎、青春宝、胡庆余堂、苍松、国风、神象等多个品牌为中国驰名商标。公司药品生产严格执行中国新版GMP要求，有多个原料药或制剂通过了WHO、FDA、欧盟以及其他发达国家的质量认证。

上海医药的分销网络以中国经济最发达的华东、华北、华南三大重点区域为中心辐射全国各地，业务规模排名全国第二。公司分销业务以医院纯销为主，并与全球40多家跨国药企开展合作。公司的疫苗、高端耗材、DTP（高值药品直送）及SPD（医药物流管理技术）等新业务发展在国内处于领先地位。公司分销服务正逐步走向以供应链延伸服务和临床支持服务为核心的医院现代服务解决方案，为医院客户提供终端解决方案、专项物流和信息化服务。

上海医药零售拥有华氏、雷允上、余天成、人寿天、雷蒙、科园信海大药房等诸多知名品牌，覆盖全国12个省、直辖市及自治区，门店总数1792家。2012年公司药品零售销售规模居全国药品零售行业前五位，上海华氏大药房为华东地区拥有药房最多的企业。上海医药的零售业务包括连锁药店、合办药房、DTP 药房等多种业态，并积极发展电子商务实现网上销售。

上海医药倡导“创新、诚信、合作、包容、责任”的企业核心价值观，致力于持之以恒，提升民众的健康生活品质，努力打造受人尊敬、拥有行业美誉度的领先品牌药制造商和健康领域服务商。

Shanghai Pharmaceuticals Holding Co., Ltd.(hereinafter as Shanghai Pharma, SSE stock code 601607 and HKEx stock code 02607) is a national pharmaceutical group headquartered in Shanghai, China. The Company’s principal business covers the whole industrial value chain ranging from pharmaceutical R&D, manufacturing, distribution and retailing. The Company is ranked No. 2 in the Chinese pharmaceutical industry in terms of the composite capabilities and is the only listed pharmaceutical company holding aleading position in both pharmaceutical manufacturing and distribution in China. In 2012, the Company had reportedly the business revenues of RMB 68 billion, ranking among the top 500 Chinese enterprises. It is selected into the sample stocks of both the SSE 180 Index and CSI 300 Index, with its H shares selected into the Hang Seng Index Compositional Stocks and MSCI.

Adhering to innovation, Shanghai Pharma’s Research and development is dedicated to providing safe and effective drugs against the grave and chronic diseases. In 2012, the total investment in the R&D accounted for 4.72% of the Company’s manufacturing sales revenue. The Company has built up the R&D systems comprising both the Group’s general institute and the sub-institutes, with the Central Research Institute acting as the technical core. Undertaking over 10 State-level scientific and technological R&D projects of “The development of Major New Drugs”, the Company owns 1 State-level corporate technology center and 10 provincial/city-level corporate technology centers. The Company adopts an open mode of R&D, under which the Company has built up the strategic alliance of innovative drug R&D in collaboration with Shanghai Institute of Materia Medica, built up the joint labs in collaboration with China Pharmaceutical University and Shenyang Pharmaceutical University etc. and has been working together with the Mitsubishi Tanabe Pharma Corporation and Shanghai Fudan Zhangjiang Biopharm etc. in the R&D of innovative drugs. Meanwhile, by means of introducing projects and joint-venture development programs etc., the Company has entered into the area of therapeutic antibodies.

Shanghai Pharma’s manufacturing business provides products ranging from chemical and bio-pharms, modern Chinese medicine, healthcare products and medical devices etc., focusing on five major therapeutic areas as cardiovascular, systemic anti-infections, digestive system and immune-metabolism, neuropsychiatric as well as antineoplastic. The products are made in over 20 dosage forms, including the tablets, capsules, powder (incl. lyophilized form), mini-volume injections, eye-drops, inhalants and coagulants etc. Over 20 products have sales revenue over RMB 100 million. The Company runs a number of brands, such as SINE, Leishi, Dragon & Tiger, Qingchunbao, Huqingyutang, Cangsong, Guofeng and Shengxiang, all of which are the renowned Chinese trademarks. The Company maintains its pharmaceutical production in strict conformity with the latest version of the Chinese GMP, having a number of APIs and preparations passed the quality authentication imposed by WHO, FDA, EU and other developed countries.

Shanghai Pharma’s distribution networks focus on the Eastern China, Northern China and Southern part of China, which are the most developed areas in China, and radiates out to other areas in the country. The Company is ranked No. 2 in China in terms of business scale. The Company has its distribution business dominated by direct sales to hospitals and works strategically with over 40 multinational pharmaceutical companies around the world. The Company boasts to hold a leading position in new business development in China in respect of vaccines, high-end consumables, DTP and SPD. The Company’s distribution services have been gradually upgraded to rendering the modern hospital service solutions focusing on both the extended supply chain services and clinical supportive services, providing the hospital customers with ultimate solutions, specified logistics and information technology services.

Shanghai Pharma runs a number of the renowned brands, including Huashi, Leiyunshang, Yutiancheng, Renshoutian, Leimeng and Keyuanxinhai Pharmacy etc., with a sales network comprising of a total 1,792 drugstores covering 12 provinces, autonomous regions and municipalities. In 2012, the Company was ranked among the top 5 players in the nationwide drug-retailing industry in terms of sales revenues and the Huashi chain Pharmacy runs the largest number of drugstores in East China area. The retailing business of Shanghai Pharma includes diversified business models, comprising the chain drugstores, joint-venture drugstores and DTP drugstores etc. Meanwhile, the Company also takes the initiatives to develop the e-business for sales online.

Adhering to the corporate’s core conceptions that are described as “innovation, integrity, cooperation, inclusiveness and responsibility”, Shanghai Pharma is always dedicated to the enhancement of people’s enjoyment of a healthier living condition, while endeavoring to be recognized as an esteemed manufacturer of the leading-brand pharmaceutical products and service provider in the healthcare industry with a sound reputation.